Answers are grounded in this paper and cite their sources.
Initial single-agent studies of anti–epidermal growth factor receptor (anti-EGFR) antibodies in the treatment of colorectal cancer showed that these agents were marginally effective.1,2 The minority of patients derived benefit, as evidenced by progression-free survival curves that had no inflection until well after the 50% mark. However, after the determination that activating mutations in exon 2 of the gene KRAS predicted the inefficacy of anti-EGFR antibodies, reanalyses of multiple trials suggested that these agents could be more effective when administered to a more limited cohort of patients.3 Thus, mutations in exon 2 of KRAS became the first biomarkers of colorectal . . .
No takes yet. Share an insight, caveat, or question.
Jordan Berlin (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: